Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
Rheumatology (Oxford, England)|September 20, 2011
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisPaul Emery, Philip J Mease, Andrea Rubbert-Roth, et al.Frontline Gastroenterology|October 29, 2019
Immunotherapy-related hepatitis: real-world experience from a tertiary centreVincent Cheung, Tarun Gupta, Miranda Payne, et al.European Journal of Cancer (Oxford, England : 1990)|June 22, 2020
Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanomaHenry G Smith, Jessica Glen, Nancy Turnbull, et al.The Journal of Rheumatology|October 3, 2012
Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX studyEdward C Keystone, Stanley B Cohen, Paul Emery, et al.Pharmacoeconomics|March 20, 2017
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Angela Boland, et al.Journal of Materials Chemistry. A|August 4, 2025
Impact of N-heterocyclic amine modulators on the structure and thermal conversion of a zeolitic imidazole frameworkJavier Castells-Gil, Jinjie Zhu, Ioanna Itskou, et al.Clinical Endocrinology|March 25, 2026
Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and RecoveryShani A D Mathara Diddhenipothage, Jacqui Warden, Katie Herbert, et al.Journal for Immunotherapy of Cancer|October 9, 2020
Impact of age on the toxicity of immune checkpoint inhibitionAmit Samani, Shuai Zhang, Laura Spiers, et al.Clinical Sarcoma Research|August 18, 2018
Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcomaRuth E Macpherson, Sarah Pratap, Helen Tyrrell, et al.Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.Pageof 4